FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
Le Lézard,
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics…
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society…
- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics…
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society…
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society…
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics…
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society…
Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating…
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT0393…
Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating…
Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating…
Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating…
- Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating…
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients…
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients…
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients…
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients…
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients…
Ideally, these contracts help address criticism of the 340B program, improve patient outcomes, and increase compliance.
Medication adherence, diet, and exercise are each critical components in caring for patients with a chronic illness, but each…
Many HTCs use these drug pricing arrangements to reduce reliance on limited federal funding.
For children and young people with hemophilia the transition to adulthood can be a complicated, challenging time -- not only…